Mesoblast Acquires CAR Platform, Ryoncil Nears US$100M Sales and DMD IND
Mesoblast projects to double net revenues as Ryoncil approaches US$100 million net sales since launch last year. FDA cleared an IND for a registrational Duchenne muscular dystrophy trial and the company acquired a CAR technology platform from Mayo Clinic to enhance its MSC product pipeline.
1. Ryoncil Commercial Growth
Mesoblast outlined a commercial strategy targeting to double net revenues by scaling Ryoncil® sales as the therapy approaches US$100 million in net revenue since its launch last year.
2. Clinical Developments
Enrollment for the Phase 3 chronic low back pain trial closes at month-end while adult steroid-refractory aGvHD sites prepare to activate this quarter following IRB clearance; the FDA cleared an IND for a registrational Duchenne muscular dystrophy trial.
3. CAR Technology Acquisition
The company acquired a patented CAR technology platform developed at Mayo Clinic, designed to precision-enhance its mesenchymal stromal cell products and support next-generation allogeneic therapies.
4. R&D Day Event
Mesoblast is hosting its inaugural R&D Day in New York with a live webcast to update on near- and mid-term blockbuster opportunities, platform innovations and commercial growth plans.